Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05825950 · ClinicalTrials.gov registry record
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
A clinical trial of Non-muscle Invasive Bladder Cancer, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- 600
- Enrollment target
- 2
- Study locations
NCT05825950 is a study of Non-muscle Invasive Bladder Cancer that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 600 participants, above the 212-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (183% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT05825950, a study of Non-muscle Invasive Bladder Cancer, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multi-center study and the aim is to develop and validate an Artificial Intelligence (AI) -based histologic analysis tool to predict responsiveness to intravesical Bacillus Calmette-Guérin (BCG) and intravesical chemotherapy in intermediate and high-risk non-muscle invasive bladder cancer patients.
Conditions Studied
Study Locations (2)
Texas
- University of Texas Southwestern Medical Center - Dallas
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-01-25 |
| Est. Completion | 2026-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05825950
The ClinicalTrials.gov registry entry for NCT05825950 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 212-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (183% higher). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05825950 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05825950 about?
NCT05825950 is a clinical study titled "Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)". This is a multi-center study and the aim is to develop and validate an Artificial Intelligence (AI) -based histologic analysis tool to predict responsiveness to intravesical Bacillus Calmette-Guérin (BCG) and intravesical chemotherapy in intermediate and high-risk non-muscle invasive bladder cancer ...
What is the current status of trial NCT05825950?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2024-01-25. Estimated completion is 2026-09.
What conditions does trial NCT05825950 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer.
Who is sponsoring clinical trial NCT05825950?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05825950 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
RECRUITING · Phase 1
-
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
-
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
RECRUITING · Phase 2
-
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
RECRUITING · Phase 2
-
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.